ELUT Stock — Elutia Inc.: Cash, EV, Pipeline

Share price

$0.85

Market cap

$37.6M

Cash

$19.9M

Enterprise value

$48.8M

Balance sheet

Cash	$19.9M
Debt	$31.1M
Net cash	-$11.2M
Enterprise value	$48.8M
Basic shares	44.2M shares
Fully diluted shares	58.0M shares
Fully diluted market cap	$49.3M
Cash per share	$0.45

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading ELUT daily closes…

Loading price history…

Pipeline assets

SimpliDerm

Approved · Active Modality: device (biologic matrix)

Partnerships Sale of SimpliDerm business pending under asset purchase agreement; disposition expected Q3 2026 (buyer not named in this filing)

Indications

Plastic and reconstructive surgery (Approved)

Status note Commercial biologic matrix product; sale pending, expected Q3 2026 subject to closing conditions.

Cardiovascular products

Approved · Active Modality: device (biologic matrix)

Partnerships Cook Biotech (now Evergen): exclusive worldwide license to porcine SIS-ECM technology plus exclusive supply; agreements expire December 31, 2028 (auto-renew two additional two-year periods); license runs to expiration of last licensed patent (expected 2031)

Indications

Cardiovascular surgical repair (Approved)

Status note Sold directly to hospitals through independent sales agents since May 2025 (prior LeMaitre Vascular distribution agreement terminated April 2025).

NXT-41

Stage not disclosed · Active Modality: device (biologic matrix)

Partnerships not disclosed

Indications

Reconstructive surgery (Stage not disclosed)

Catalysts

— None

Status note Next-generation porcine-derived engineered biologic scaffold; FDA marketing authorization expected in the second half of 2026.

NXT-41x

Stage not disclosed · Active Modality: combination product (biologic matrix with local antibiotics)

Partnerships not disclosed

Indications

Reconstructive surgery (implant infections) (Stage not disclosed)

Catalysts

— None

Status note Biologic scaffold with local antibiotics for implant infections; FDA clearance anticipated by mid-2027.

Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	EluPro Antibiotic-Eluting BioEnvelope
Lead indication	Cardiac Arrhythmias
Lead phase	Not disclosed
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06854081	Not disclosed	Active, not recruiting	Sponsor	ELUT	—	Cardiac Arrhythmias	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Elutia Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

ELUT — Elutia Inc.

Balance sheet

Price history

Pipeline assets

Pipeline

Active clinical trials